Healthcare & Life Sciences
Embedded and adjacent health technology
Clinical software is valued on how difficult it is to remove. There is a simple diligence test for which side of that line a product sits on.
Healthcare software covers products with very different economics under a single label. Revenue cycle management, clinical documentation, patient engagement, scheduling and analytics all sell into the same buyer, and all describe themselves in similar terms. Acquirers separate them on one axis: how hard the product is to remove.
The test
The practical diligence test is what happens if the customer stops paying. If a clinical or billing process stops, the software is embedded. If someone reverts to a spreadsheet or to a manual workflow and the organisation continues to function, it is adjacent.
Embedded products show it in the numbers. Net retention above one hundred percent, low logo churn, and renewal cycles that are administrative rather than competitive. Adjacent products, however well built, compete again at every renewal, and their retention reflects that even when their customer satisfaction does not.
Integration cuts both ways
Depth of integration into the electronic health record is the most common source of embeddedness, and it is also the feature that most shapes the buyer universe.
To a strategic acquirer with an adjacent product and no integration of its own, a deep EHR integration is a large part of what is being bought. To an acquirer that already carries a competing integration, the same asset is a migration cost. The two will value the identical business very differently, which is an argument for knowing which is which before deciding who to approach.
What diligence examines
Beyond retention, three areas reliably attract attention. Contract assignability, because health systems frequently negotiate consent rights that a change of control triggers. Security and privacy posture, where the question is not whether a breach has occurred but whether the documentation would withstand a customer audit. And dependence on specific integration partners, where a single upstream relationship can represent concentration risk that the revenue split does not reveal.
If a meaningful share of revenue sits behind contracts requiring consent on a change of control, that is worth mapping before a process rather than discovering during one. Consent campaigns take time, and a buyer that learns about them late will assume the worst about the ones you have not yet secured.
Contact
Thirty minutes, without materials or obligation. We will give you a considered view of value, of what is currently constraining it, and of whether this is the right point at which to act.
Where our view is that you should wait, we will say so.
Contact us